Keros Therapeutics, Inc. Insider Trading for April 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Keros Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Keros Therapeutics, Inc. for April 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 100,211 | |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 61.23 | 233 | 14,267 | 0 | 233 to 0 (-100.00 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 60.01 | 367 | 22,024 | 233 | 600 to 233 (-61.17 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 59.09 | 400 | 23,636 | 600 | 1,000 to 600 (-40.00 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 5,300 | 1,590 | 135,005 | |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 61.72 | 100 | 6,172 | 71,187 | 71.3 K to 71.2 K (-0.14 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 61.08 | 729 | 44,527 | 71,287 | 72 K to 71.3 K (-1.01 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 59.99 | 3,473 | 208,345 | 72,016 | 75.5 K to 72 K (-4.60 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 59.10 | 998 | 58,982 | 75,489 | 76.5 K to 75.5 K (-1.30 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 5,300 | 1,590 | 76,487 | 71.2 K to 76.5 K (+7.45 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.95 | 35 | 2,098 | 402,015 | 402.1 K to 402 K (-0.01 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.95 | 54 | 3,237 | 601,146 | 601.2 K to 601.1 K (-0.01 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.10 | 2,402 | 141,958 | 402,050 | 404.5 K to 402.1 K (-0.59 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.10 | 3,685 | 217,784 | 601,200 | 604.9 K to 601.2 K (-0.61 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.22 | 1,233 | 71,785 | 404,452 | 405.7 K to 404.5 K (-0.30 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.22 | 1,889 | 109,978 | 604,885 | 606.8 K to 604.9 K (-0.31 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.26 | 6,972 | 420,133 | 405,685 | 412.7 K to 405.7 K (-1.69 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.26 | 10,690 | 644,179 | 606,774 | 617.5 K to 606.8 K (-1.73 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.76 | 3,551 | 212,208 | 412,657 | 416.2 K to 412.7 K (-0.85 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.76 | 5,445 | 325,393 | 617,464 | 622.9 K to 617.5 K (-0.87 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.66 | 195 | 11,439 | 416,208 | 416.4 K to 416.2 K (-0.05 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.66 | 298 | 17,481 | 622,909 | 623.2 K to 622.9 K (-0.05 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.36 | 134 | 8,222 | 416,403 | 416.5 K to 416.4 K (-0.03 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.36 | 206 | 12,640 | 623,207 | 623.4 K to 623.2 K (-0.03 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.82 | 283 | 17,212 | 416,537 | 416.8 K to 416.5 K (-0.07 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.82 | 434 | 26,396 | 623,413 | 623.8 K to 623.4 K (-0.07 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.08 | 1,533 | 90,570 | 416,820 | 418.4 K to 416.8 K (-0.37 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.08 | 2,350 | 138,838 | 623,847 | 626.2 K to 623.8 K (-0.38 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.42 | 2,472 | 144,414 | 418,353 | 420.8 K to 418.4 K (-0.59 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.42 | 3,790 | 221,412 | 626,197 | 630 K to 626.2 K (-0.60 %) |
| Apr 02 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 9,996 | 1,100 | 0 | |
| Apr 02 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 9,996 | 1,100 | 71,187 | 61.2 K to 71.2 K (+16.34 %) |